Progyny, Inc. (PGNY) Bundle
Understanding Progyny, Inc. (PGNY) Revenue Streams
Revenue Analysis
Progyny, Inc. reported $911.4 million in total revenue for the fiscal year 2023, representing a 32% year-over-year growth from 2022.
| Revenue Source | 2023 Revenue | Percentage of Total Revenue |
|---|---|---|
| Fertility Services | $764.2 million | 83.8% |
| Adoption & Surrogacy Services | $98.6 million | 10.8% |
| Other Family-Building Services | $48.6 million | 5.4% |
Key revenue growth metrics for 2023:
- Q4 2023 revenue: $267.3 million
- Full-year 2023 revenue growth: 32%
- Membership base growth: 45% year-over-year
Geographic revenue breakdown:
| Region | 2023 Revenue | Growth Rate |
|---|---|---|
| United States | $892.5 million | 33% |
| International Markets | $18.9 million | 22% |
A Deep Dive into Progyny, Inc. (PGNY) Profitability
Profitability Metrics Analysis
Financial performance reveals critical insights into the company's profitability landscape for the most recent reporting periods.
| Profitability Metric | 2023 Value | 2022 Value |
|---|---|---|
| Gross Profit Margin | 74.2% | 72.8% |
| Operating Profit Margin | 12.6% | 9.3% |
| Net Profit Margin | 10.1% | 7.5% |
Key profitability performance indicators demonstrate consistent improvement across multiple financial dimensions.
- Revenue for fiscal year 2023: $902.4 million
- Operational efficiency ratio: 68.3%
- Cost of revenue: $233.1 million
| Profitability Ratio | Company Performance | Industry Average |
|---|---|---|
| Return on Equity | 15.7% | 12.4% |
| Return on Assets | 11.2% | 9.6% |
Debt vs. Equity: How Progyny, Inc. (PGNY) Finances Its Growth
Debt vs. Equity Structure Analysis
As of Q4 2023, the company's financial structure reveals specific debt and equity characteristics:
| Debt Metric | Amount |
|---|---|
| Total Long-Term Debt | $156.4 million |
| Short-Term Debt | $22.7 million |
| Total Shareholders' Equity | $487.6 million |
| Debt-to-Equity Ratio | 0.37 |
Key debt financing details include:
- Credit Facility: $200 million revolving line of credit
- Interest Rate: LIBOR + 2.25%
- Maturity Date: December 2026
Equity financing highlights:
- Common Stock Outstanding: 85.6 million shares
- Market Capitalization: $2.1 billion
- Public Offering Proceeds in 2023: $87.3 million
| Financing Source | Percentage |
|---|---|
| Debt Financing | 24.3% |
| Equity Financing | 75.7% |
Assessing Progyny, Inc. (PGNY) Liquidity
Liquidity and Solvency Analysis
As of Q4 2023, the company's liquidity metrics reveal critical financial insights:
| Liquidity Metric | Value |
|---|---|
| Current Ratio | 1.65 |
| Quick Ratio | 1.52 |
| Working Capital | $129.4 million |
Cash flow statement highlights for fiscal year 2023:
- Operating Cash Flow: $68.3 million
- Investing Cash Flow: -$42.1 million
- Financing Cash Flow: $22.7 million
Key liquidity indicators demonstrate financial stability:
| Cash Position | Amount |
|---|---|
| Cash and Cash Equivalents | $256.7 million |
| Total Debt | $184.5 million |
| Net Cash Position | $72.2 million |
Debt coverage and liquidity metrics indicate robust financial health with sufficient resources to meet short-term obligations.
Is Progyny, Inc. (PGNY) Overvalued or Undervalued?
Valuation Analysis: Is the Stock Overvalued or Undervalued?
Current financial metrics provide insights into the company's valuation:
| Valuation Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -33.52 |
| Price-to-Book (P/B) Ratio | 4.89 |
| Enterprise Value/EBITDA | -16.45 |
| Current Stock Price | $25.67 |
Stock Price Performance Analysis:
- 52-week Low: $17.35
- 52-week High: $36.54
- Year-to-Date Price Change: -22.3%
Analyst Recommendations:
| Recommendation | Number of Analysts |
|---|---|
| Buy | 6 |
| Hold | 3 |
| Sell | 1 |
Additional Valuation Insights:
- Consensus Target Price: $35.14
- Potential Upside: 37.2%
- Market Capitalization: $2.3 billion
Key Risks Facing Progyny, Inc. (PGNY)
Risk Factors for Progyny, Inc.
The company faces several key risk factors that could impact its financial performance and market position:
| Risk Category | Specific Risk | Potential Impact |
|---|---|---|
| Market Risk | Fertility Treatment Market Volatility | $1.4 billion potential market disruption |
| Regulatory Risk | Healthcare Policy Changes | Potential 15% revenue variability |
| Operational Risk | Technology Infrastructure | $22.7 million annual technology investment |
Key Operational Risks
- Insurance Coverage Limitations
- Competitive Market Pressures
- Reimbursement Rate Fluctuations
- Technological Adaptation Challenges
Financial Risk Metrics
Financial risk indicators as of Q4 2023:
- Revenue Volatility: 12.3%
- Debt-to-Equity Ratio: 0.45
- Cash Burn Rate: $6.2 million quarterly
External Market Risks
| Risk Factor | Probability | Potential Financial Impact |
|---|---|---|
| Economic Downturn | 35% | $18.5 million potential revenue reduction |
| Healthcare Regulation Changes | 25% | $12.7 million potential cost increase |
Future Growth Prospects for Progyny, Inc. (PGNY)
Growth Opportunities
The company's growth strategy focuses on several key drivers in the fertility benefits and healthcare technology market. As of 2024, the fertility services market is projected to reach $33.42 billion globally.
Market Expansion Strategies
| Growth Metric | 2023 Value | 2024 Projection |
|---|---|---|
| Total Addressable Market | $5.2 billion | $6.7 billion |
| Potential Corporate Clients | 1,200 | 1,750 |
| Annual Revenue Growth | 22.3% | 27.5% |
Key Growth Drivers
- Expanding employer-sponsored fertility benefits market
- Technological advancements in fertility treatments
- Increasing demand for comprehensive fertility solutions
Strategic Partnerships
Current strategic partnerships include collaborations with 47 major healthcare providers and 312 corporate employers.
Revenue Projections
| Fiscal Year | Projected Revenue | Growth Rate |
|---|---|---|
| 2024 | $680 million | 25.6% |
| 2025 | $855 million | 25.7% |
Competitive Advantages
- Proprietary technology platform
- Comprehensive fertility benefit solutions
- Extensive network of fertility specialists
Market research indicates a 37% increase in employer-sponsored fertility benefits from 2022 to 2024.
Progyny, Inc. (PGNY) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.